NMRA Neumora Therapeutics, Inc.
Legal ·
A Securities Act suit in New York names Neumora, certain executive officers and certain underwriters. Defendants' reply on their motion to dismiss the second amended complaint is due August 24, 2026.
Neumora Therapeutics is ending development of navacaprant after its two Phase 3 KOASTAL trials in major depressive disorder missed statistical significance. It cut about 35% of its workforce and amended a loan with K2 HealthVentures, and it says its cash will last into the third quarter of 2027.
Nasdaq told Neumora Therapeutics on May 14, 2025 that it is below the $1.00 minimum bid price requirement. The company is weighing a reverse stock split, with a stockholder vote set for May 28, 2025.
The company has until November 10, 2025 to regain compliance. Stockholders vote on a possible reverse stock split on May 28, 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $176.1 million | $200.9 million |
| Net income (loss) | -$236.9 million | -$243.8 million |
| Cash from operations | -$206.4 million | -$182.9 million |
| Cash and equivalents | $182.5 million | $142.1 million |
| Short-term investments | $165.4 million |
Our latest story on this, dated May 16, 2025: "Neumora gets Nasdaq minimum bid price notice, has until November 10, 2025 to comply". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "Neumora IPO class action over navacaprant disclosures awaits ruling on dismissal motion". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "Neumora IPO class action over navacaprant disclosures awaits ruling on dismissal motion". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 16, 2025: "Neumora Therapeutics gets Nasdaq notice for stock below $1.00 bid price". The story links the filing or release it is based on. Read the story.
Neumora Therapeutics, Inc. trades under the ticker NMRA on NASDAQ.
Neumora Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Neumora Therapeutics, Inc. is 1885522. Its filings are on SEC EDGAR.
187,895,912 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Neumora Therapeutics, Inc. under United States.
Our directory classifies Neumora Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Neumora Therapeutics, Inc. is US6409791000.
aibio.space lists Neumora Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Neumora Therapeutics, Inc. reported a net loss of $236.9 million for the fiscal year ended Dec 31, 2025, and used $206.4 million of cash in operations, per its annual report to the SEC.
$176.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.03,2.05,7.01,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio